WFH/X
Jul 29, 2025, 13:12
AAV Gene Therapies for Hemophilia A and B: Current Perspectives
The World Federation of Haemophilia (WFH) shared a proud post on X:
“Gene Therapy is transforming Hemophilia care. A new review highlights how AAV-based treatments for hemophilia A and B are delivering long-term results—some lasting years with just one dose. Challenges remain, but the future is promising.
Read more.”
Title: Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Authors: Roland W. Herzog, Radoslaw Kaczmarek, Katherine A. High
Stay informed with Hemostasis Today.
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026
-
Jul 13, 2026, 15:42Marc Carrier: Important New Data From the API-CAT Trial on Recurrent VTE During Extended Apixaban Therapy